P
Philippe Maingon
Researcher at University of Paris
Publications - 261
Citations - 17363
Philippe Maingon is an academic researcher from University of Paris. The author has contributed to research in topics: Radiation therapy & Prostate cancer. The author has an hindex of 49, co-authored 238 publications receiving 14930 citations. Previous affiliations of Philippe Maingon include European Organisation for Research and Treatment of Cancer & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Preoperative radiotherapy and surgery for endometrial carcinoma: prognostic significance of the sterilization of the specimen.
Philippe Maingon,Laurent Arnould,Valérie Magnin,Françoise Collin,Catherine Belichard,J. Fraisse,I. Barillot,A. d’Hombres,Marie-Christine Bone-Lepinoy,Marie-Martine Padeano,Serge Douvier,Jean Cuisenier,Jean-Claude Horiot +12 more
TL;DR: Preoperative radiotherapy followed by surgery is a safe and effective treatment of FIGO stage I or II endometrial carcinomas and BT with two uterine tubes seems to be of interest in the contribution of the treatment of the uterus to sterilize the specimen.
Journal ArticleDOI
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials
Yungan Tao,Anne Auperin,Pierre Graff,Michel Lapeyre,Vincent Grégoire,Philippe Maingon,Lionel Geoffrois,Pierre Verrelle,Gilles Calais,Bernard Gery,Laurent Martin,Marc Alfonsi,Patrick Deprez,Etienne Bardet,Thierry Pignon,Michel Rives,Christian Sire,Jean Bourhis,Jean Bourhis +18 more
TL;DR: The outcome of N3 HNSCC was extremely poor despite treatment intensification and no difference between CRT and VART, and both distant metastases and loco-regional failures remain important treatment challenge.
Journal ArticleDOI
An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?
F. Bonnetain,J.F. Bosset,Jean-Pierre Gerard,Gilles Calais,T. Conroy,L. Mineur,O. Bouche,Philippe Maingon,Olivier Chapet,L. Radosevic-Jelic,N. Methy,L. Collette +11 more
TL;DR: Despite increased statistical power, CRT that prolonged LC as compared to RT alone, failed to prolong OS or PFS, and future phase III trials may use OS and PFS as primary endpoint to ensure clinical benefit.
Journal ArticleDOI
Nasal cavity and paranasal sinus cancer
TL;DR: The nasal cavity and parasinusal cancer are rare (10% of tumors of the head and neck) and are mainly represented by squamous cell carcinomas of the nasal cavity or the maxillary sinus and adenocarcinoma of the ethmoid sinus.
Journal ArticleDOI
Qualité de vie chez les patients traités pour un cancer de la sphère ORL
Philippe Maingon,Gilles Créhange,F. Bonnetain,A. Ligey-Bartolomeu,J. Chamois,Y. Bruchon,P. Romanet,Gilles Truc +7 more
TL;DR: Il appartient a la communaute des oncologues radiotherapeutes de prendre conscience of l’importance of ces facteurs and of se les approprier afin qu’ils soient desormais integres comme des instruments d’analyses pertinents de l”efficacite des traitements.